Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
The treatment of cancer cells obtained by blocking cellular metabolism has received a lot of attention recently. Previous studies have demonstrated that Kras mutation-mediated abnormal glucose metabolism would lead to an aberrant cell proliferation in human pancreatic ductal adenocarcinoma (PDAC) ce...
Main Authors: | Wei-Chia Hung, Der-Yen Lee, En-Pei Isabel Chiang, Jia-Ning Syu, Che-Yi Chao, Mei-Due Yang, Shu-Yao Tsai, Feng-Yao Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0241186 |
Similar Items
-
KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
by: Shuang-Ni Yu, et al.
Published: (2016-12-01) -
Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
by: Yasuki Hori, et al.
Published: (2015-01-01) -
Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
by: Jing Gao, et al.
Published: (2021-05-01) -
Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma
by: Huai-Qiang Ju, et al.
Published: (2017-02-01) -
Correction: impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
by: PLOS ONE Staff
Published: (2015-01-01)